[vc_row][vc_column width=”1/2″ css=”.vc_custom_1407326566064{padding-right: 25px !important;}”][vc_column_text]

Our solution

QureTech Bio is developing a new class of antibacterial agents that may have broad-spectrum activity against Chlamydia and other pathogens. Termed virulence blockers, these agents selectively disarm the pathogenic capability of certain bacteria, without affecting normal bacterial flora, and therefore decrease the selection pressure for resistance development. Initial observations indicate a set of compounds that are effective against Chlamydia but non- toxic to human cell lines. Hence, these type of drugs can replace most of the antibiotics currently used to treat Chlamydia infections.[/vc_column_text][vc_single_image image=”115″ border_color=”grey” img_link_target=”_self” img_size=”medium” style=”vc_box_circle” img_link_large=”” alignment=”center”][/vc_column][vc_column width=”1/2″ css=”.vc_custom_1407326584603{padding-right: 25px !important;}”][info_list position=”left” style=”square with_bg” icon_border_style=”none” icon_border_size=”1″ border_color=”#333333″ connector_color=”#333333″ icon_bg_color=”#ffffff” icon_color=”#333333″ font_size_icon=”16″][info_list_item icon_type=”selector” list_icon=”Defaults-exclamation-sign” animation=”swing”]The compounds comprise a new class of pharmaceuticals termed virulence blockers. This new class of compounds prevents disease by specifically blocking virulence properties of pathogenic bacteria, including multi- resistant strains. Development of resistance will probably be attenuated.[/info_list_item][info_list_item icon_type=”selector” list_icon=”Defaults-exclamation-sign” animation=”swing”]Proof-of-principle biological data suggest diverse target modes of action in different bacteria, potentiating the development of several virulence blockers.[/info_list_item][info_list_item icon_type=”selector” list_icon=”Defaults-exclamation-sign” animation=”swing”]Virulence blockers specifically target infectious microorganisms – they do not affect host cells or normal bacterial flora in the intestinal canal and respiratory tract. Both factors contribute to low side-effects.[/info_list_item][info_list_item icon_type=”selector” list_icon=”Defaults-exclamation-sign” animation=”swing”]Unlike current antibiotics used to treat Chlamydia, the company’s compound is effectively targeting Chlamydia at two separate points of its lifecycle. This is relevant in light of reports stating that standard single antibiotic courses (two weeks) only kill at one of its three life phases, leaving live forms of the bacteria, which are in other stages, to renew infection.[/info_list_item][info_list_item icon_type=”selector” list_icon=”Defaults-exclamation-sign” animation=”swing”]High probability of obtaining fast track status from regulatory bodies.[/info_list_item][/info_list][/vc_column][/vc_row]